Research Analysts Issue Forecasts for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Stock analysts at Roth Capital reduced their Q1 2025 earnings per share estimates for CervoMed in a report issued on Tuesday, March 18th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.80) per share for the quarter, down from their prior estimate of ($0.52). Roth Capital has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Roth Capital also issued estimates for CervoMed’s Q2 2025 earnings at ($0.73) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($2.47) EPS.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.13). The business had revenue of $2.16 million during the quarter, compared to analyst estimates of $1.51 million. CervoMed had a negative net margin of 118.68% and a negative return on equity of 44.11%.

Several other research firms have also recently weighed in on CRVO. Morgan Stanley reaffirmed an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of CervoMed in a research report on Monday, March 17th. HC Wainwright cut CervoMed from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 17th. Canaccord Genuity Group upped their price objective on CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Roth Mkm increased their price target on CervoMed from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, CervoMed has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

CervoMed Price Performance

CRVO stock opened at $14.29 on Thursday. The stock has a market capitalization of $88.17 million, a P/E ratio of -7.04 and a beta of 1.84. The business has a 50-day moving average of $3.30 and a 200-day moving average of $7.87. CervoMed has a fifty-two week low of $1.80 and a fifty-two week high of $25.92.

Institutional Trading of CervoMed

Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC bought a new stake in CervoMed in the third quarter valued at approximately $56,000. Barclays PLC raised its stake in CervoMed by 323.6% in the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after buying an additional 5,919 shares during the period. Virtu Financial LLC bought a new stake in CervoMed in the fourth quarter valued at approximately $26,000. DRW Securities LLC bought a new stake in CervoMed in the fourth quarter valued at approximately $30,000. Finally, Mariner LLC bought a new stake in CervoMed in the fourth quarter valued at approximately $30,000. Institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.